Stay updated on Safety of CVL-231 in Schizophrenia: Clinical Trial
Sign up to get notified when there's something new on the Safety of CVL-231 in Schizophrenia: Clinical Trial page.

Latest updates to the Safety of CVL-231 in Schizophrenia: Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check24 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check60 days agoChange DetectedThe page has undergone significant content removal, particularly regarding the details of a clinical trial for emraclidine in schizophrenia, including the study's purpose, inclusion and exclusion criteria, and the previous version's revision number. The only notable addition is a new revision number.SummaryDifference23%
Stay in the know with updates to Safety of CVL-231 in Schizophrenia: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of CVL-231 in Schizophrenia: Clinical Trial page.